---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-012334"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2021-09-09T23:59:59+00:00"
generated_at: "2026-06-29T04:54:05.361593+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immuneering Q2 net loss $7.9M; IPO raised $129.4M; IMM-1-104 IND expected Q1 2022

## Summary
- Net loss of $7.9M ($1.61/share) vs $3.6M ($0.73/share) in Q2 2020.
- Cash $50.2M at June 30, 2021; excludes $118.3M net IPO proceeds from August 2021.
- R&D expenses $7.0M, up from $3.2M YoY on preclinical costs and personnel.
- Completed upsized IPO of 8.625M shares at $15.00/share for $129.4M gross.
- IND filing for IMM-1-104 (RAF-MEK inhibitor) planned for Q1 2022; Phase 1 start H1 2022.

## SEC filing metadata
- accession: 0001558370-21-012334
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2021-09-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000155837021012334/0001558370-21-012334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000155837021012334/imrx-20210909x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-012334
- JSON: https://secwatch.observer/filing/0001558370-21-012334.json
- Plain text: https://secwatch.observer/filing/0001558370-21-012334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.